Samsung Electronics shareholders question Exynos chipset performance Some shareholders link throttling controversy with tech giant’s new chipset performance
Translated by Ryu Ho-joung 공개 2022-03-18 08:14:57
이 기사는 2022년 03월 18일 08시14분 thebell에 표출된 기사입니다
As expected by many, the controversy over performance throttling in gaming apps on Galaxy S22 smartphones was at the center of Samsung Electronics’ annual general meeting on Wednesday, leading to an official apology by its top executive at the meeting.Samsung Electronics vice chairman Han Jong-hee bowed to shareholders at the general meeting held in Suwon, Gyeonggi Province, in his apology for the performance throttling scandal, saying, “We apologize for worrying shareholders and customers”.
The main culprit was the so-called Game Optimizing Service (GOS), which is pre-installed on the tech giant’s latest mobile devices. GOS was originally designed to fine-tune system performance during gaming for longer battery life and thermal management. But it drew strong complaints from mobile gaming users as an option to disable the function was not provided.
The GOS controversy, combined with other headwinds such as the Ukraine crisis and the US Federal Reserve's anticipated tightening, put downward pressure on Samsung Electronics shares, with the stock price falling to below 70,000 won ($57.30) per share on Tuesday.
In response to the criticism that consumer trust in Samsung’s smartphones has declined following the performance throttling scandal, Han said the company would ensure to prevent such an issue from recurring and put customer experience as its top priority.
Samsung later rolled out a software update to allow users to control the performance while running gaming apps. When asked by a shareholder if that could raise overheating concerns again, Han answered that the company’s thermal control algorithm would help optimize the device condition to secure safety.
Some shareholders linked the GOS scandal with Samsung’s latest Exynos 2200 mobile chip, pointing out that the new chipset’s weak performance could be the root cause of the throttling issue.
“Exynos showed better performance than Qualcomm’s Snapdragon when Galaxy S2 and S3 series were rolled out in the past, but now there are even rumors that the Galaxy series were equipped with Mediatek’s APs, which used to be considered chips for cheaper mobile devices,” another shareholder said to the management at the general meeting.
Kyung Kye-hyun, president and chief executive officer of the company’s Device Solutions business, answered to the shareholder that a strategy related to chipsets depends on market changes and the company’s circumstances, excusing his limited explanation due to the confidential nature of the information.
“I wanted to know the company’s future plans and vision for Exynos 2200 but couldn’t get a sufficient answer from the management,” said one shareholder who attended Samsung’s general meeting.
Samsung launched Exynos 2200 earlier this year, which features the Xclipse GPU, the first mobile GPU based on AMD technology. However, it is said that the new chipset was used in the Galaxy S22 series sold in certain regions such as Europe while Qualcomm’s Snapdragon 8 Gen 1 was used in the rest of the markets, drawing attention to the reason.
Samsung’s share in the global smartphone application processor market was 4% in the fourth quarter of last year, down by three percentage points from a year ago, according to data from Counterpoint Research. The company fell to fifth place behind Taiwan’s Mediatek (33%), Qualcomm (30%), Apple (21%) and China’s UNISOC (11%). This contrasts with Samsung holding an over 14% share in the market in 2019, overtaking Apple.
Meanwhile, the company’s all board nominees were elected at the general meeting, despite opposition by some minority shareholders to an insider director nominee who they say is responsible for the throttling scandal. (Reporting by Hyun-ji Sohn)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [i-point]'자가면역질환 신약' 이노보테라퓨틱스, 미국 임상 1상 '성공적'
- [i-point]폴라리스오피스, 엔비디아 ‘커넥트’ 공식 파트너 선정
- [i-point]신성이엔지, 한국종합기술·다스코와 연료전지 발전사업 협약
- [i-point]신테카바이오, 'PEGS 보스턴 2025' 참가
- [AACR 2025]첫 구두발표 진씨커, 경쟁사 넘보는 '유전자가위 액체생검'
- [AACR 2025]이뮨온시아 'CD47' 안전성 굳히기 "경쟁약과 다르다"
- [AACR 2025]항암 신약 항체 대신 '페라틴', 셀레메디 플랫폼 데뷔전
- [AACR 2025]근거 쌓는 '루닛 스코프' 빅파마 공동연구 쇼케이스
- [변곡점 선 콜마비앤에이치]변화의 마지막 카드, 경영진 교체 '강수' 두나
- [변곡점 선 콜마비앤에이치]속절없는 주가 하락 '트리거', 주가 부양 의지 없었나